DexCom (NASDAQ:DXCM) Issues Quarterly Earnings Results

DexCom (NASDAQ:DXCM) released its quarterly earnings results on Thursday. The medical device company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03, FiscalAI reports. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.84%. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.45 earnings per share.

Here are the key takeaways from DexCom’s conference call:

• Broad U.S. rollout of Dexcom G7 15‑day is underway with early market feedback praising longer wear and the company’s best‑to‑date accuracy, and management is actively building awareness to drive adoption.
• Strong Q4 performance—$1.26B revenue (+13% YoY), Q4 gross margin of 63.5%—and a 2025 milestone of >$1 billion free cash flow, ending the quarter with ~ $2B cash after settling convertible notes and a $300M buyback.
• Meaningful upside from expanded access if Medicare covers Type 2 non‑insulin (management cites ~12M lives); Dexcom plans an RCT readout mid‑2026 to support coverage decisions and payer adoption.
• 2026 guidance targets revenue of $5.16–$5.25B (11–13% growth) and 63–64% gross margin, while planned investments—including hiring and the Ireland manufacturing ramp late in 2026—may moderate near‑term OpEx leverage.

DexCom Stock Performance

NASDAQ DXCM opened at $70.02 on Friday. DexCom has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The stock has a market cap of $27.31 billion, a P/E ratio of 33.34, a PEG ratio of 1.17 and a beta of 1.49. The company’s 50-day simple moving average is $69.03 and its 200 day simple moving average is $69.74.

Analysts Set New Price Targets

DXCM has been the topic of several recent analyst reports. Robert W. Baird set a $87.00 target price on shares of DexCom in a report on Friday. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research note on Friday. Argus cut their price objective on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Truist Financial reaffirmed a “buy” rating and issued a $82.00 target price (down previously from $94.00) on shares of DexCom in a report on Monday, November 3rd. Finally, Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $85.27.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat expectations: DexCom reported $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY); management reiterated 2026 guidance, supporting near-term outlook. Dexcom beats quarterly estimates
• Positive Sentiment: G7 15‑day sensor rollout and margin gains cited as growth drivers — management pointed to product adoption and improving margins as catalysts for revenue and profitability expansion. G7 rollout drives growth
• Positive Sentiment: Mizuho raised its price target to $90 (outperform), signaling confidence in longer‑term upside and helping buy‑side sentiment. Mizuho price target raise
• Positive Sentiment: BTIG reaffirmed a Buy rating with an $85 target, adding to analyst support that underpins the rally. BTIG reaffirmation
• Positive Sentiment: Product/AI initiative — the Stelo AI upgrade aims to deepen consumer metabolic-health engagement, which could expand recurring usage and ARPU over time. Stelo AI upgrade
• Neutral Sentiment: Analyst activity is mixed overall: several firms maintained or raised targets while at least one adjusted its price target (see below). This creates both support and some variability in near-term expectations. Wall Street analyst targets
• Neutral Sentiment: Trading indicators: intraday volume is notably above the stock’s average, which amplifies price moves but can increase short-term volatility. (Background market data)
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous zero/NaN values and a 0.0 days‑to‑cover figure — the data appears unreliable and should be treated cautiously by traders monitoring short activity.
• Negative Sentiment: Wells Fargo trimmed its price target from $93 to $85 despite keeping an Overweight rating, a modest negative signal that reduces the high‑end analyst consensus. Wells Fargo target cut

Institutional Investors Weigh In On DexCom

Large investors have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of DexCom by 6.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock worth $530,897,000 after buying an additional 516,526 shares during the period. CIBC Private Wealth Group LLC raised its stake in DexCom by 7.6% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock worth $207,613,000 after acquiring an additional 220,313 shares in the last quarter. Neuberger Berman Group LLC lifted its holdings in shares of DexCom by 111.6% during the fourth quarter. Neuberger Berman Group LLC now owns 2,340,199 shares of the medical device company’s stock valued at $155,319,000 after acquiring an additional 1,234,469 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of DexCom by 29.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,871,705 shares of the medical device company’s stock valued at $124,245,000 after purchasing an additional 427,139 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of DexCom by 71.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,444,796 shares of the medical device company’s stock valued at $95,891,000 after purchasing an additional 603,232 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.